ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2023-6-3-58-63ojrdrt-317Research ArticleКОМБИНИРОВАННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯCOMBINED METHODS OF DIAGNOSTICS AND TREATMENTГлиобластома головного мозга. Финансово-экономические аспекты терапии (обзор литературы)Glioblastoma of the Brain. Financial and Economic Aspects of Therapy. Literature Reviewhttps://orcid.org/0000-0002-6714-6413КарташевА. В.KartashevA. V.

Карташев Артём  Владимирович — к.м.н., врач-радиотерапевт, с.н.с. отдела лучевых и комбинированных методов лечения; доцент кафедры лучевой диагностики и лучевой терапии

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, 70; 191015, Санкт-Петербург, Кирочная ул., 41

70, Leningradskaya str., Pesochny, St. Petersburg, 197758; 41, Kirochnaya str., St. Petersburg, 191015

arxiator@mail.ruhttps://orcid.org/0000-0002-0938-5213ВиноградоваЮ. Н.VinogradovaYu. N.

Виноградова Юлия Николаевна — д.м.н., врач-радиотерапевт, рукуководитель отдела лучевых и комбинированных методов лечения; доцент кафедры радиологии, хирургии и онкологии РНЦ радиологии и хирургических технологий им. ак. А.М. Гранова

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, 70

70, Leningradskaya str., Pesochny, St. Petersburg, 197758

winogradova68@mail.ruРоссийский научный центр радиологии и хирургических технологий им. ак. А.М. Гранова Минздрава России; Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава РоссииРоссияA.M. Granov Russian Research Center of Radiology and Surgical Technologies; I.I. Mechnikov North-West State Medical UniversityRussian FederationРоссийский научный центр радиологии и хирургических технологий им. ак. А.М. Гранова Минздрава РоссииРоссияA.M. Granov Russian Research Center of Radiology and Surgical TechnologiesRussian Federation202315102023635863Copyright © Карташев А.В., Виноградова Ю.Н., 20232023Карташев А.В., Виноградова Ю.Н.Kartashev A.V., Vinogradova Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/317

Заболеваемость злокачественными опухолями центральной нервной системы (ЦНС) по всему миру продолжает расти. Лечение данной группы пациентов требует сложных и дорогостоящих диагностических и терапевтических технологий. Таким образом, злокачественные опухоли головного мозга оказывают значительное социально-экономическое воздействие на пациентов, их семьи и системы здравоохранения во всем мире.

На сегодня отсутствует систематический обзор затрат на лечение пациентов с опухолями головного мозга, хотя отдельные исследования подчеркивают важность этой проблемы. Кроме того, каждое исследование проводится с использованием разных методов лечения и имеет собственные затраты, что делает невозможным сравнение затрат между странами. Тем не менее, общая картина указывает на то, что злокачественные опухоли являются наиболее финансово обременительными видами опухолевого поражения головного мозга. На наш взгляд, необходимо проведение точных и международно-сопоставимых исследований, которые уделяли бы особое внимание косвенным и нематериальным затратам. Это позволит более полно понять экономическое воздействие этого заболевания и определить использование ресурсов здравоохранения. 

Malignant brain tumors include primary and metastatic brain tumors. The incidence and prevalence of malignant tumors of the central nervous system (CNS) around the world continue to grow. Treatment of this group of patients requires complex and expensive diagnostic and therapeutic technologies. Thus, malignant brain tumors, whether primary or metastatic, have a significant socio-economic impact on patients, their families and healthcare systems around the world. At the moment, there is no systematic review of the costs of treating patients with brain tumors, although some studies emphasize the importance of this problem. 

головной мозгзлокачественные опухолиглиобластомаметастазы в головной мозгэкономическое бремяиспользование ресурсов здравоохраненияmalignant brain tumorsbrain metastasesglioblastomaeconomic burdenuse of health resourcesИсследование выполнено в рамках госзадания № 37.8-2021 № 121040200139-1. Разработка функционально-адаптивной радиохирургии опухолей головного мозга путем применения методики функциональной диагностики зон топического представительства скелетных мышцThe study was carried out within the framework of state task No. 37.8-2021 No. 121040200139-1. Development of functional adaptive radiosurgery of brain tumors by applying the technique of functional diagnostics of areas of topical representation of skeletal musclesReferencesSacks P, Rahman M. Epidemiology of Brain Metastases. Neurosurg Clin N Am. 2020 Oct;31(4):481-488. doi: 10.1016/j.nec.2020.06.001.Sacks P, Rahman M. Epidemiology of Brain Metastases. Neurosurg Clin N Am. 2020 Oct;31(4):481-488. doi: 10.1016/j.nec.2020.06.001.GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Apr;18(4):376-393. doi: 10.1016/S1474-4422(18)30468-X.GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Apr;18(4):376-393. doi: 10.1016/S1474-4422(18)30468-X.Lee YR, Cho B, Jo MW et al. Measuring the Economic Burden of Disease and Injury in Korea, 2015. J Korean Med Sci. 2019 Mar 7;34(Suppl 1):e80. doi: 10.3346/jkms.2019.34.e80.Lee YR, Cho B, Jo MW et al. Measuring the Economic Burden of Disease and Injury in Korea, 2015. J Korean Med Sci. 2019 Mar 7;34(Suppl 1):e80. doi: 10.3346/jkms.2019.34.e80.Guy GP Jr, Ekwueme DU, Yabroff KR et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013 Oct 20;31(30):3749-57. doi: 10.1200/JCO.2013.49.1241.Guy GP Jr, Ekwueme DU, Yabroff KR et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013 Oct 20;31(30):3749-57. doi: 10.1200/JCO.2013.49.1241.Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005 Oct;75(1):5-14. doi: 10.1007/s11060-004-8093-6.Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005 Oct;75(1):5-14. doi: 10.1007/s11060-004-8093-6.Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27-42. doi: 10.1016/B978-0-12-811161-1.00002-5.Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27-42. doi: 10.1016/B978-0-12-811161-1.00002-5.Ostrom QT, Patil N, Cioffi G et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200.Ostrom QT, Patil N, Cioffi G et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200.Perkins N. The high price of brain tumours. 2020. Available from: https://www.braintumourresearch.org/media/our-blog/blogitem/our-blog/2020/03/27/the-high-price-of-braintumours.Perkins N. The high price of brain tumours. 2020. Available from: https://www.braintumourresearch.org/media/our-blog/blogitem/our-blog/2020/03/27/the-high-price-of-braintumours.Cagney DN, Alexander BM. The cost and value of glioblastoma therapy. Expert Rev Anticancer Ther. 2017 Aug;17(8):657-659. doi: 10.1080/14737140.2017.1351355.Cagney DN, Alexander BM. The cost and value of glioblastoma therapy. Expert Rev Anticancer Ther. 2017 Aug;17(8):657-659. doi: 10.1080/14737140.2017.1351355.Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989 Nov 24;262(20):2879-86. doi: 10.1001/jama.262.20.2879.Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989 Nov 24;262(20):2879-86. doi: 10.1001/jama.262.20.2879.Belotti Masserini A, Zeni S, Cossutta R et al. Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti [Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients]. Reumatismo. 2003 Oct-Dec;55(4):245-55. Italian. doi: 10.4081/reumatismo.2003.245.Belotti Masserini A, Zeni S, Cossutta R et al. Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti [Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients]. Reumatismo. 2003 Oct-Dec;55(4):245-55. Italian. doi: 10.4081/reumatismo.2003.245.Choi HJ, Lee EW. Methodology of Estimating Socioeconomic Burden of Disease Using National Health Insurance (NHI) Data [Internet]. Evaluation of Health Services. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.89895Choi HJ, Lee EW. Methodology of Estimating Socioeconomic Burden of Disease Using National Health Insurance (NHI) Data [Internet]. Evaluation of Health Services. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.89895Ries LA, Harkins D, Krapcho MF et al. (2006). SEER Cancer Statistics Review, 1975-2003.Ries LA, Harkins D, Krapcho MF et al. (2006). SEER Cancer Statistics Review, 1975-2003.Liu R, Page M, Solheim K et al. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol. 2009 Jun;11(3):330-9. doi: 10.1215/15228517-2008-093.Liu R, Page M, Solheim K et al. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol. 2009 Jun;11(3):330-9. doi: 10.1215/15228517-2008-093.Casado V, Romero L, Gubieras L et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 2007 Jul;13(6):800-4. doi: 10.1177/1352458506073480.Casado V, Romero L, Gubieras L et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler. 2007 Jul;13(6):800-4. doi: 10.1177/1352458506073480.Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. PMID: 29251870.Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 8. PMID: 29251870.Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec;32(12):1201-12. doi: 10.1007/s40273-014-0198-y.Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec;32(12):1201-12. doi: 10.1007/s40273-014-0198-y.Wick W, Osswald M, Wick A et al. Treatment of glioblastoma in adults. Ther Adv Neurol Disord. 2018 Jul 25;11:1756286418790452. doi: 10.1177/1756286418790452.Wick W, Osswald M, Wick A et al. Treatment of glioblastoma in adults. Ther Adv Neurol Disord. 2018 Jul 25;11:1756286418790452. doi: 10.1177/1756286418790452.Mendez I, Jacobs P, MacDougall A et al. Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci. 2001 Feb;28(1):61-5. doi: 10.1017/s0317167100052574.Mendez I, Jacobs P, MacDougall A et al. Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci. 2001 Feb;28(1):61-5. doi: 10.1017/s0317167100052574.Wasserfallen JB, Ostermann S, Pica A et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004 Nov 1;101(9):2098-105. doi: 10.1002/cncr.20619.Wasserfallen JB, Ostermann S, Pica A et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004 Nov 1;101(9):2098-105. doi: 10.1002/cncr.20619.Hamilton D. Evidence, economics, and emotions: the case for temozolomide. N Z Med J. 2005 Dec 16;118(1227):U1774. PMID: 16372024.Hamilton D. Evidence, economics, and emotions: the case for temozolomide. N Z Med J. 2005 Dec 16;118(1227):U1774. PMID: 16372024.Lamers LM, Stupp R, van den Bent MJ, et al. EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297.Lamers LM, Stupp R, van den Bent MJ, et al. EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297.Chandra A, Young JS, Dalle Ore C, et al. Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma. J Neurosurg. 2019 Jun 21:1-11. doi: 10.3171/2019.3.JNS182629.Chandra A, Young JS, Dalle Ore C, et al. Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma. J Neurosurg. 2019 Jun 21:1-11. doi: 10.3171/2019.3.JNS182629.Undabeitia J, Torres-Bayona S, Samprón N, et al. Indirect costs associated with glioblastoma: Experience at one hospital. Neurologia (Engl Ed). 2018 Mar;33(2):85-91. English, Spanish. doi: 10.1016/j.nrl.2016.05.003.Undabeitia J, Torres-Bayona S, Samprón N, et al. Indirect costs associated with glioblastoma: Experience at one hospital. Neurologia (Engl Ed). 2018 Mar;33(2):85-91. English, Spanish. doi: 10.1016/j.nrl.2016.05.003.Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 Jan;11(1):e59-65. doi: 10.1200/JOP.2012.000560.Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 Jan;11(1):e59-65. doi: 10.1200/JOP.2012.000560.Brain Tumor – Symptoms and Signs. Cancer. Net. 2020. Available from: https://www.cancer.net/cancer-types/brain-tumor/symptoms-and-signs. Accessed 11 Jan 2021.Brain Tumor – Symptoms and Signs. Cancer. Net. 2020. Available from: https://www.cancer.net/cancer-types/brain-tumor/symptoms-and-signs. Accessed 11 Jan 2021.Sagberg LM, Solheim O, Jakola AS. Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg. 2016 Apr;124(4):989-97. doi: 10.3171/2015.4.JNS15194.Sagberg LM, Solheim O, Jakola AS. Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg. 2016 Apr;124(4):989-97. doi: 10.3171/2015.4.JNS15194.Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol. 2013 Aug;114(1):117-25. doi: 10.1007/s11060-013-1160-0.Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol. 2013 Aug;114(1):117-25. doi: 10.1007/s11060-013-1160-0.

The authors declare that there are no conflicts of interest present.